ALSO NOTED: Antisoma gets $25M milestone; Takeda pays out retention bonuses; and much more...

> Novartis has kicked off a late-stage trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer, triggering a $25 million milestone payment to Antisoma. Release

> Following the $8.8 billion acquisition of Millennium, Takeda will fork over retention bonuses to Millennium employees to prevent them from jumping ship. Report

> Health experts say that an outbreak of mumps two years ago among college students occurred even though most of them had received a recommended vaccine. Report

> Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. Report

> An outbreak of dengue fever in and around Rio de Janeiro has afflicted more than 75,000 people since the beginning of the year, with 12 people dying in just the past week. Report

> The transplant drug probe is widening. FDA says it's identified 16 cases of an often-fatal neurological disease among patients taking Roche's CellCept drug, used to prevent organ rejection. Report

> Pharma knows that self-regulation is the best kind. That's why 12 drug and device makers have promised Sen. Chuck Grassley that they are working on plans to disclose CME grants. Report

> When Jean-Pierre Garnier makes his exit from GlaxoSmithKline next month, he'll walk away with the promise of a $4.9 billion options bonus that will pay off sometime in 2010. Report

And Finally... If you want to market your drug to patients, a new study shows the Web is not the place to do it. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.